FDA Approves Treatment for Kidney Transplant Patients

Article

Envarsus protects against organ rejection in transplant patients who switch from other twice-daily tacrolimus products.

Envarsus protects against organ rejection in transplant patients who switch from other twice-daily tacrolimus products.

The FDA on Monday approved a new therapeutic option for kidney transplant patients.

Envarsus XR is a once-daily tacrolimus extended-release tablet that protects against organ rejection in kidney transplant patients who require conversion from other twice-daily tacrolimus products. Envarsus is expected to be available in the United States by the fourth quarter of 2015.

Envarsus XR offers an extended release formulation of tacrolimus with flatter pharmacokinetics (PK) and greater bioavailability compared with twice-daily tacrolimus, according to manufacturer Veloxis Pharmaceuticals.

The FDA approval followed a pair of phase 3 trials and several phase 2 trials in kidney transplant patients. In all of the trials, once daily Envarsus showed significantly higher bioavailability and a flatter PK profile than current leading transplant drug Prograf (immediate release tacrolimus) dosed twice-daily.

"We are very pleased to have a new treatment option available for kidney transplant recipients," Anthony Langone, MD, associate professor and medical director of the Medical Specialties Clinic at Vanderbilt University said in a press release. "Patients must receive immunosuppression as lifelong therapy and Envarsus XR holds promise for kidney transplant patients and their physicians as a tacrolimus product with the convenience of once-daily dosing."

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.